KR100574153B1 - 아지트로마이신의 결정형 - Google Patents

아지트로마이신의 결정형 Download PDF

Info

Publication number
KR100574153B1
KR100574153B1 KR1020037015125A KR20037015125A KR100574153B1 KR 100574153 B1 KR100574153 B1 KR 100574153B1 KR 1020037015125 A KR1020037015125 A KR 1020037015125A KR 20037015125 A KR20037015125 A KR 20037015125A KR 100574153 B1 KR100574153 B1 KR 100574153B1
Authority
KR
South Korea
Prior art keywords
azithromycin
type
ppm
weight
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037015125A
Other languages
English (en)
Korean (ko)
Other versions
KR20040014525A (ko
Inventor
리젱제인
트라스크앤드류빈센트
Original Assignee
화이자 프로덕츠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100574153(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 프로덕츠 인코포레이티드 filed Critical 화이자 프로덕츠 인코포레이티드
Publication of KR20040014525A publication Critical patent/KR20040014525A/ko
Application granted granted Critical
Publication of KR100574153B1 publication Critical patent/KR100574153B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020037015125A 2001-05-22 2002-05-01 아지트로마이신의 결정형 Expired - Fee Related KR100574153B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US60/292,565 2001-05-22
US29774101P 2001-06-12 2001-06-12
US60/297,741 2001-06-12
US34304101P 2001-12-21 2001-12-21
US60/343,041 2001-12-21
PCT/IB2002/001570 WO2002094843A1 (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Publications (2)

Publication Number Publication Date
KR20040014525A KR20040014525A (ko) 2004-02-14
KR100574153B1 true KR100574153B1 (ko) 2006-04-25

Family

ID=27404135

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037015125A Expired - Fee Related KR100574153B1 (ko) 2001-05-22 2002-05-01 아지트로마이신의 결정형

Country Status (35)

Country Link
US (10) US6977243B2 (https=)
EP (1) EP1390377B1 (https=)
JP (3) JP2004530703A (https=)
KR (1) KR100574153B1 (https=)
AP (1) AP2003002906A0 (https=)
AR (1) AR036022A1 (https=)
AT (2) ATE404575T1 (https=)
AU (1) AU2002256846B2 (https=)
BG (1) BG108370A (https=)
BR (1) BR0209918A (https=)
CA (1) CA2391659C (https=)
CR (1) CR7159A (https=)
CZ (1) CZ20033154A3 (https=)
DE (2) DE60228345D1 (https=)
DK (1) DK1390377T3 (https=)
EA (2) EA007618B1 (https=)
EE (1) EE200300575A (https=)
ES (2) ES2258142T3 (https=)
GE (1) GEP20084399B (https=)
HU (1) HUP0400446A2 (https=)
IL (1) IL158591A0 (https=)
IS (1) IS7007A (https=)
MA (1) MA27023A1 (https=)
MX (1) MXPA03010028A (https=)
MY (1) MY129319A (https=)
NO (2) NO321894B1 (https=)
NZ (2) NZ529118A (https=)
PA (1) PA8545701A1 (https=)
PE (1) PE20021064A1 (https=)
PL (1) PL367091A1 (https=)
PT (1) PT1390377E (https=)
SK (1) SK14402003A3 (https=)
TN (1) TNSN03121A1 (https=)
WO (1) WO2002094843A1 (https=)
YU (1) YU91603A (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
SI20639A (sl) * 1998-11-30 2002-02-28 Teva Pharmaceutical Industries Ltd. Etanolat azitromicina, postopek za njegovo pripravo in njegovi farmacevtski sestavki
JP2004506664A (ja) * 2000-08-23 2004-03-04 ウォックハート・リミテッド 無水アジトロマイシンの製造法
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
ES2258142T3 (es) * 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
PL371259A1 (pl) 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
RU2283092C2 (ru) 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1878432A1 (en) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Single dose fast dissolving azithromycin
ATE421882T1 (de) * 2003-07-24 2009-02-15 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
EP1687308B1 (en) * 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
WO2007004230A2 (en) * 2005-07-05 2007-01-11 Hetero Drugs Limited A novel process for the preparation of didanosine using novel intermediates
JP2009501206A (ja) * 2005-07-14 2009-01-15 ファイザー・プロダクツ・インク 非晶質アジスロマイシン粒子の生成方法
BRPI0616040A2 (pt) * 2005-09-21 2011-06-07 Nycomed Gmbh cloridrato de sulfonilpirról como inibidor de histona desacetilases
EP2404911A1 (en) * 2005-10-31 2012-01-11 Janssen Pharmaceutica NV Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2667345C (en) * 2006-10-27 2016-03-22 Signal Pharmaceuticals, Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US20120058936A1 (en) 2009-03-13 2012-03-08 Assistance Publique - Hopitaux De Paris Compositions and methods for elimination of gram negative bacteria
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
EP2760859A1 (en) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Crystalline forms of azilsartan and preparation and uses thereof
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
KR20170139074A (ko) 2015-04-24 2017-12-18 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
IL326637A (en) * 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43116B (en) * 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) * 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
WO1989000576A1 (en) * 1987-07-09 1989-01-26 Pfizer Inc. Azithromycin dihydrate
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DE69730138T2 (de) * 1996-07-29 2005-03-03 Abbott Laboratories, Abbott Park Herstellung von kristallinen form ii von clarithromycin
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
SI20639A (sl) * 1998-11-30 2002-02-28 Teva Pharmaceutical Industries Ltd. Etanolat azitromicina, postopek za njegovo pripravo in njegovi farmacevtski sestavki
AU5820400A (en) * 1999-06-29 2001-01-31 Biochemie S.A. Macrolides
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
EP1246831B1 (en) 2000-01-04 2008-03-05 Teva Pharmaceutical Industries Ltd. Preparation method of azithromycin dihydrate
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
DE60026718T2 (de) * 2000-07-25 2006-11-16 Laboratorio Silanes, S.A. De C.V. Einstufiges verfahren zur herstellung von 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle(11.2.11)hexadeca-1(2)-en-8-ona undeine neue form von 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
JP2004506664A (ja) 2000-08-23 2004-03-04 ウォックハート・リミテッド 無水アジトロマイシンの製造法
HRP20030430B1 (hr) 2000-11-27 2011-11-30 Biochemie S.A. Makrolidni solvati
IN190080B (https=) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ES2258142T3 (es) * 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
ES2324527T3 (es) 2001-10-18 2009-08-10 Teva Pharmaceutical Industries Ltd. Composiciones de azitromicina estabilizadas.

Also Published As

Publication number Publication date
DE60209704D1 (de) 2006-05-04
US20050256063A1 (en) 2005-11-17
EP1390377B1 (en) 2006-03-08
ATE404575T1 (de) 2008-08-15
DE60209704T2 (de) 2006-11-16
US20040138149A1 (en) 2004-07-15
CR7159A (es) 2004-02-23
US6977243B2 (en) 2005-12-20
MY129319A (en) 2007-03-30
SK14402003A3 (sk) 2004-06-08
US20050245469A1 (en) 2005-11-03
US7309782B2 (en) 2007-12-18
IS7007A (is) 2003-10-30
EA200500630A1 (ru) 2006-02-24
NZ529118A (en) 2005-10-28
NO20035177D0 (no) 2003-11-21
US20040082527A1 (en) 2004-04-29
JP2004530703A (ja) 2004-10-07
PL367091A1 (en) 2005-02-21
EE200300575A (et) 2004-04-15
BR0209918A (pt) 2004-03-30
AR036022A1 (es) 2004-08-04
YU91603A (sh) 2006-08-17
MA27023A1 (fr) 2004-12-20
ATE319730T1 (de) 2006-03-15
DK1390377T3 (da) 2006-06-19
JP4584162B2 (ja) 2010-11-17
ES2258142T3 (es) 2006-08-16
HUP0400446A2 (hu) 2004-09-28
US20040043945A1 (en) 2004-03-04
PE20021064A1 (es) 2002-11-21
US20050256062A1 (en) 2005-11-17
ES2310886T3 (es) 2009-01-16
BG108370A (bg) 2004-11-30
NO20061049L (no) 2003-05-12
US7053192B2 (en) 2006-05-30
CA2391659C (en) 2006-05-30
US20040043944A1 (en) 2004-03-04
JP2007161726A (ja) 2007-06-28
US7282486B2 (en) 2007-10-16
EA007618B1 (ru) 2006-12-29
DE60228345D1 (de) 2008-09-25
TNSN03121A1 (en) 2005-12-23
PT1390377E (pt) 2006-06-30
US20030162730A1 (en) 2003-08-28
JP2006152002A (ja) 2006-06-15
IL158591A0 (en) 2004-05-12
EA009611B1 (ru) 2008-02-28
CA2391659A1 (en) 2002-11-22
KR20040014525A (ko) 2004-02-14
US7081525B2 (en) 2006-07-25
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
US20050090459A1 (en) 2005-04-28
US7105179B2 (en) 2006-09-12
AP2003002906A0 (en) 2003-12-31
NO321894B1 (no) 2006-07-17
EP1390377A1 (en) 2004-02-25
US7307156B2 (en) 2007-12-11
AU2002256846B2 (en) 2007-04-05
GEP20084399B (en) 2008-06-10
WO2002094843A1 (en) 2002-11-28
MXPA03010028A (es) 2004-02-12
EA200301115A1 (ru) 2004-04-29
NZ539801A (en) 2006-10-27
CZ20033154A3 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
KR100574153B1 (ko) 아지트로마이신의 결정형
AU2002256846A1 (en) Crystal Forms of Azithromycin
CN100354294C (zh) 阿奇霉素的晶形
EP1671979B1 (en) New Cristal Form of Azithromycin
CA2536501C (en) Crystal forms of azithromycin
EP0952157B1 (en) 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090420

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090420